p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 2123-2127

  Giannikaki, E ^a   Kouvidou, Ch ^a   Tzardi, M ^a   Stefanaki, K ^a   Koutsoubi, K ^a   Gregoriou, M ^a   Zois, E ^a   Kakolyris, S ^a   Mavroudi, C ^a   Delides, G ^a   Georgoulias, V ^a,b   Kanavaros, P ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Breast carcinoma; mdm2; p2l waf1; p53 protein

Indexed keywords

PROTEIN P21; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CANCER GENETICS; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030812191     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Levine A, Momand J, Finlay C: The p53 tumour suppressor gene. Nature 351: 453-456, 1992.
2. Nigro MJ, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989.
3. Gaidano G, Ballerini P, Gonz JZ, et al: P53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88: 5413-5417, 1991.
4. Villuendas R, Piris MA, Algara P, Sanchez-Beato M, Sanchez-Verde L, Martinez JC, et al: The expression of p53 protein in breast carcinomas is not always dependent on p53 gene mutations. Blood 82: 3151-3156, 1993.
5. Kocialkowski S, Pezzela F, Morrison H, Jones M, Laha S, Harris AL, et al: Mutations in the p53 gene are not limited to classic "hot spots" and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br J Haematol 89: 55-60, 1995.
6. Barak Y, Oren M: Enhanced binding of a 95 kd protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J 11: 2115-2121, 1992.
7. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm2 oncogene product forms a complex with p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
8. Oliner JD, Pietenpol JA, Thiagalingam S, et al: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860, 1993.
9. Finlay CA: The mdm2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301-306, 1993.
10. Juven T, Barak Y, Zauberman A, George DL, Oren M: Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8: 3411-3416, 1993.
11. Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm2 autoregulatory feedback loop. Genes & Dev 7: 1126-1132, 1993.
12. Chen CY, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, Kastan MB: Interactions between p53 and mdm2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 91: 26844-2691, 1994.
13. El -Deiry WS, Tokino T, Velculesku VE, Levy DB, Parsons R, Trent JM, et al: Waf1, a potential mediator of p53 tumour suppression. Cell 75: 817-825, 1993.
14. Harper JW, Adami GY, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdkintteracting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 75: 805-816, 1993.
15. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: P21 is universal inhibitor of cyclin kinase. Nature 366: 701-704, 1993.
16. Gu Y, Turk CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20 k regulatory subunit. Nature 366: 707-710, 1993.
17. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinase controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.
18. Walker RA, Dearing SI, Lane DP, Varvey JM: Expression of p53 protein in infiltrating and in situ breast carcinomas. J Pathol 165: 203-211, 1991.
19. Bosari S, Lee AKC, Viale G, Heatley GJ, Coggi G: Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with longterm follow-up. Virch Archiv A (Pathol and Histopathol) 421: 291-295, 1992.
20. Umekita Y, Takasaki T, Yoshida H: Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, noninvasive and invasive mammary carcinoma: an immunohistochemical study. Virch Archiv 424: 491-494, 1994.
21. Davidoff A, Humphrey P, Inglehas D, Marks J: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88: 5006-5010, 1991.
22. Thompson A, Anderson T, Condie A: p53 allele losses, mutations and expression in breast cancer and their relationship to clinicopathologicai parameters. Int J Cancer 50: 528-532, 1992.
23. Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, et al: P53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 164: 75-81, 1991.
24. Karameris AM, Worthy E, Gorgoulis V, Quezado M, Anastasiades O TH: P53 gene alterations in special types of breast carcinoma: a molecular and immunohistochemical study in archival material. J Pathol 176: 361-372, 1995.
25. Marchetti A, Buttitta F, Girlando S, Dalla Pama P, Pellegrini S, et al: Mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J of Pathol 175: 31-38, 1995.
26. Me Cann AH, Kirley A, Carney DN, Corbally N, Magee HM, et al: Amplification of the mdm2 gene in human breast cancer and its association with mdm2 and p53 protein status. Br J Cancer 71: 981-985, 1995.
27. Cordell JL, Falini B, Erber WN, et al: Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APMP COMPLEXES). J Histochem Cytochem 32: 219-222, 1984
28. Kanavaros P, Kouvidou Ch, Dai Y, Tzardi M, Datseris G, Darivianaki K, et al: MDM2 protein expression in nasopharyngeal carcinomas. Comparative study with p53 protein expression. J Clin Pathol: Mol Pathol 48: M322-M325, 1995.
29. Ladanyi M, Cha Ch, Lewis R, et al: MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53: 16-18, 1993.
30. Reiferberger G, Liu L, Ichimura K, Schmidt EE, Coilins VP: Amplification and overexpression of the MDM2gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739, 1993.
31. Sheikh MS, Shao ZM, Hussain A, Fontana JA: The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 53: 3226-3228, 1993.
32. Bueso-Ramos CE, Yang Y, Leon E, et al: The human MDM2 oncogene is overexressed in leukemias. Blood 82: 2617-2623, 1993.
33. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, et al: The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low grade lymphoma of B-cell origin. Blood 9: 3158-3165, 1994.
34. Chilosi M, Doglioni C, Menestrina F, Montagna L, Rigo A, Lestani MS, et al: Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood 84: 4295-4300, 1994.
35. Oliner JD, Pietenpol JA, Thiagalingam S, et al: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860, 1993.
36. Landers JE, Haines DS, Straus JF, George DL: Enhanced translation: a novel model of mdm2 oncogene overexpression identified in human tumour cells. Oncogene 9: 2745-2751, 1994.
37. Martinez JC, Mateo MS, Sanchez-Beato M, Villuendas R, Orrade JL, Algara P, et al: MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. J Pathol 177: 27-35, 1995.
38. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, Houseini ME: Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 9: 3389-3396, 1994.